Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) - CANTATA

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) - CANTATA

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Cabozantinib (Primary) ; Telaglenastat (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms CANTATA
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 07 Jan 2019 According to Calithera Biosciences media release, the company expects to reach enrollment of this study by 2H 2019.
    • 07 Nov 2018 According to Calithera Biosciences media release, top-line results from this study are expected in 2020.
    • 07 Nov 2018 Planned number of patients changed from 300 to 400, according to Calithera Biosciences media release. The trial was originally designed to enroll 300 patients which has been enlarged to approximately 400 patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top